BioXcel Therapeutics, Inc. (BTAI) is a Biotechnology company in the Healthcare sector, currently trading at $1.05. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is BTAI = $12 (+1042.9% upside).
Valuation: BTAI trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $642,000, +86.8%/yr average growth. Net income is $70M (loss), growing at +15.1%/yr. Net profit margin is -10887.4% (negative). Gross margin is 27.7% (-67 pp trend).
Balance sheet: total debt is $110M with negative equity of -$95M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.83 (tight liquidity). Debt-to-assets is 244%. Total assets: $45M.
Analyst outlook: 8 / 15 analysts rate BTAI as buy (53%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 0/100 (Fail), Moat 14/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
